Eyepoint Pharmaceuticals reported promising topline LUGANO trial results for its sustained release TKI in wet AMD, strengthening the case for longer acting reti

Eyepoint Pharmaceuticals reported promising topline LUGANO trial results for its sustained release TKI in wet AMD, strengthening the case for longer acting retinal therapies. The update suggests a lower treatment burden, with no new financial or development timeline.